Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis
Por:
Rosas J, Martín-López M, Otón T, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J and Carmona L
Publicada:
1 sep 2020
Ahead of Print:
29 oct 2018
Categoría:
Rheumatology
Resumen:
Objectives: Issue recommendations on practical aspects of the monitoring of levels of biological drugs that may be useful for rheumatologists.
Methods: We conducted a systematic review of studies in which drug and anti-drug antibody levels were determined in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) to study whether they could predict different outcomes. In light of the results of the review, a group of experts discussed under what circumstances testing biological drug levels and their antibodies could be useful. The discussion resulted in a series of clinical questions that were answered with the scientific evidence collected, and in algorithms that facilitate decision making.
Results: It was established that the determination of drug levels can be especially useful in two clinical situations, on treatment failure (primary or secondary) and on sustained remission. It is also reviewed which laboratory technique and timing for sample drawing are the most suitable for the measurement. Recommendations are issued on the interpretation of drug levels and on factors to be taken into account (for example, body mass index and disease modifying drugs).
Conclusions: Evidence-based algorithms and guidelines have been established to test drug levels and anti-drug antibodies in patients with RA and SpA, which can help clinical decision making. (C) 2018 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.
Filiaciones:
:
Sección de Reumatología, Hospital Marina Baixa , Villajoyosa, Alicante, España
Seccion de Reumatologia, Hospital Marina Baixa , Villajoyosa, Alicante, Espana
Martín-López M:
Servicio de Reumatología, Hospital Universitario 12 de Octubre, Madrid, España
Servicio de Reumatologia, Hospital Universitario 12 de Octubre, Madrid, Espana
Otón T:
Instituto de Salud Musculoesquelética (Inmusc), Madrid, España
Instituto de Salud Musculoesqueletica (Inmusc), Madrid, Espana
Balsa A:
Servicio de Reumatología, Hospital Universitario La Paz, Madrid, España
Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Espana
Calvo-Alén J:
Servicio de Reumatología, Hospital Universitario Araba, Vitoria, España
Servicio de Reumatologia, Hospital Universitario Araba, Vitoria, Espana
Sanmartí R:
Servicio de Reumatología, Hospital Clínic de Barcelona, Barcelona, España
Servicio de Reumatologia, Hospital Clinic de Barcelona, Barcelona, Espana
Tornero J:
Servicio de Reumatología, Hospital General Universitario de Guadalajara, Guadalajara, España
Servicio de Reumatologia, Hospital General Universitario de Guadalajara, Guadalajara, Espana
Carmona L:
Instituto de Salud Musculoesquelética (Inmusc), Madrid, España
Instituto de Salud Musculoesqueletica (Inmusc), Madrid, Espana
Open Access
FULL TEXT
 |
Published Version |
This policy does not allow for Open Access for this version. |
| No Accesible |
|